Overall, our study provides important preclinical evidence that targeting PIN1/CDK1 axis is an appealing strategy to suppress tumor growth and metastasis, and sensitize cancer cells to chemotherapies by stabilizing pVHL in TNBC. The gene discussed is CDK1; the disease is neoplasm.